Bayer AG News Conference Call
Bayer: Good performance in a challenging environment, Group outlook confirmed
Group sales increase by 1.9 percent (Fx & portfolio adj.) to 9.905 billion euros / EBITDA before special items level year on year at 2.202 billion euros / Business performance at Pharmaceuticals remains strong / Consumer Health with increase in sales (Fx & portfolio adj.), while currency effects weigh on earnings / Crop Science posts substantial rise in sales and earnings due to acquisition – successful start to integration process / Sales and earnings of Animal Health decline following a strong second quarter / One-time gain (before taxes) of roughly 3.9 billion euros from divestments / Net income 2.886 billion euros / Core earnings per share 1.19 euros / Adjusted 2018 Group outlook confirmed
Links
Interim Report Q3 2018
Press kit
Audio: MP3 for download (6.5 MB, 54:59 min.) (dubbed into English)
Speaker
Statement in written form and presentation slides
Recording (dubbed into English):
Audio: MP3 of the speech for download (MP3, 3.0 MB, 12:40 min.)
Recording (dubbed into English):
Twitter